This page shows what was measured, who it was measured in, and what that does not settle.
What Mometasone Furoate does in the body
A steroid that comes as an asthma inhaler, a hay-fever nasal spray, a skin cream and a sinus implant
Mometasone crosses into the cells lining the airway or the nose, binds a receptor there and carries it into the nucleus, where it switches off the genes that produce inflammatory signals. It is built to stay where it is put: what escapes into the bloodstream is very small, and most of what is swallowed is destroyed by the liver before it circulates. That is why a year of the nasal spray did not slow children’s growth — and it is not a guarantee for the inhaler, which delivers more drug and still carries a growth warning.
What happened in people
No growth suppression over one year in 98 randomised children on intranasal mometasone: 6.95 cm against 6.35 cm
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
The nasal and topical forms are generic across 28 listed presentations; the inhaled and implanted forms are not
Where it acts
Airway epithelium and submucosal inflammatory cells (inhaled); nasal and sinus mucosa (spray and implant); epidermis and dermis (topical)
Kind of result
The kind of result is not recorded
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 04201GDN4R · read 2026-08-29
Its recorded molecular formula is C27H30Cl2O6, weighing 521.43.
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 136 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Absolute difference
An absolute difference is how many more people in a hundred were affected.
A picture of it, and where the picture fails
It is like counting heads in two rooms of a hundred.
Where that stops being true. Heads are easy to count. Study results carry a margin of error too.
What people get wrong. It is confused with a percentage change, which can look far larger.
The arithmetic difference in event rates between arms.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer1 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Pain
visual analog scale for pain
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
1 registered symptom measure.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Risk of adjudicated serious asthma outcome — hospitalisation, intubation or death — with mometasone furoate-formoterol against mometasone furoate alone
Hazard ratio 1.22 (95% CI 0.76 to 1.94, P=0.411) for first serious asthma outcome; 45 events in 39 patients against 36 events in 32 patients, all hospitalisations
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. The point estimate is above 1 and the trial is a noninferiority design, so the finding is the absence of a demonstrated excess rather than a demonstrated equivalence. Every serious asthma outcome in the trial was a hospitalisation; there were no intubations and no deaths.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Inhalation powder (Twisthaler) and pressurised HFA aerosol, aqueous nasal spray, topical cream, ointment and lotion, and a bioabsorbable sinus implant
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
No growth suppression: 6.95 cm against 6.35 cm at one year, growth rate 0.018 cm per day in both groups; no HPA-axis suppression on cosyntropin testing at 26 or 52 weeks
Repeated elsewhere
Unreplicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. 82 of 98 completed. A negative safety finding in 82 children is only interpretable alongside the matched study of another intranasal steroid, which detected a 0.9 cm difference at a similar size.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Inhalation powder (Twisthaler) and pressurised HFA aerosol, aqueous nasal spray, topical cream, ointment and lotion, and a bioabsorbable sinus implant
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
Growth rate significantly slower on beclometasone in both intention-to-treat and completer analyses; mean change in standing height 5.0 cm against 5.9 cm at one year
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. There was a statistically significant baseline imbalance in standing height, handled by analysis of covariance and a z-score normalisation. No hypothalamic-pituitary-adrenal axis difference was detected, so a normal cortisol test does not exclude a growth effect.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Inhalation powder (Twisthaler) and pressurised HFA aerosol, aqueous nasal spray, topical cream, ointment and lotion, and a bioabsorbable sinus implant
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
RNAWiki holds 3 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
□Living longer, or avoiding a major eventNo evidence recorded. Death, a heart attack, a stroke, a hospital stay.No registered study measures this.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.9 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.2 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
□Cells in a dishNo evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Mometasone Furoate
What a person takes: Inhalation powder (Twisthaler) and pressurised HFA aerosol, aqueous nasal spray, topical cream, ointment and lotion, and a bioabsorbable sinus implant.
The measurement behind this step
The inhaled products are maintenance treatment only and are explicitly not for relief of acute bronchospasm. The nasal spray is used once daily. The four routes are separate products with separate evidence, and the most common error made about this drug is treating a safety finding from one route as though it applied to another.
Getting in
Delivered to one surface and meant to stay there
Four products, four surfaces: a dry powder or aerosol into the lung, a spray into the nose, a cream onto skin, an implant into a sinus. The design goal in every case is to treat that surface and go no further.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Mometasone furoate as inhalation powder in the Twisthaler, as a pressurised HFA aerosol, as an aqueous nasal suspension of the monohydrate, as topical cream, ointment and lotion, and as a bioabsorbable steroid-eluting sinus implant. Each has a different deposited dose and a different absorbing surface, and the safety data from one do not transfer to another.
The furoate ester makes it lipophilic and short-lived in blood
A bulky chemical group attached to the steroid makes it stick in tissue and makes the liver destroy it quickly if it reaches the bloodstream. That combination is the whole design.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The 17-furoate ester raises lipophilicity and receptor affinity and is a substrate for rapid hepatic metabolism. Systemic bioavailability of the intranasal product is negligible, which is what the one-year paediatric growth and cosyntropin data demonstrate rather than assert.
Inside the cell it binds a receptor that normally sits waiting in the cytoplasm. It binds it more tightly than most other steroids — although the label declines to say what that means for a patient.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
In-vitro binding affinity for the human glucocorticoid receptor of approximately 12 times dexamethasone, 7 times triamcinolone acetonide, 5 times budesonide and 1.5 times fluticasone, with clinical significance stated as unknown.
The receptor carries it into the nucleus and rewrites transcription
The pair moves into the nucleus and switches inflammatory genes off. That is why a steroid takes days to work and why it is useless during an attack.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Activated receptor dimers bind glucocorticoid response elements to transactivate anti-inflammatory genes and, more importantly here, tether to and repress pro-inflammatory transcription factors. The label states that the precise mechanism of corticosteroid action on asthma is not known and describes inhibitory effects across mast cells, eosinophils, neutrophils, macrophages and lymphocytes.
The airway lining or the nasal lining becomes less swollen, less twitchy and produces less mucus. Adding a long-acting beta-agonist to it cut exacerbations by about a tenth in nearly twelve thousand people.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
In SPIRO, asthma exacerbation occurred in 708 of 5,868 on mometasone-formoterol against 779 of 5,861 on mometasone alone, hazard ratio 0.89 (95% CI 0.80 to 0.98, P=0.021), with a serious-asthma-outcome hazard ratio of 1.22 (95% CI 0.76 to 1.94, P=0.411).
A year of the nasal spray did not slow children’s growth. The inhaler is a different exposure, and its label still warns about growth, adrenal suppression, glaucoma and cataracts.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
The intranasal growth study found 6.95 cm against 6.35 cm at one year with no cosyntropin-detectable adrenal suppression. The inhaled label lists growth effects in paediatric patients, hypercorticism and adrenal suppression, and glaucoma and cataracts as Warnings and Precautions, and flags strong CYP3A4 inhibitors as raising systemic corticosteroid effects.
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 6 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
total combined symptom over the entire grass pollen season
4 nasal symptom from baseline at week 2
4 nasal symptom after 2 weeks
total nasal symptom
reflective total nasal symptom
control questionnaire from baseline to post tapered ics
total symptom
total nasal symptom averaged over day 1 through day 15
visual analog scale for pain
Measured
Things only a test, a scale or a device shows.
maximum plasma concentration
time to reach maximum concentration
Meaningful
Things that change how a life goes, not only a number.
No registered study measured anything of this kind.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (29)
apnea hypopnea index
global assessment
pharmacokinetic parameters
forced expiratory volume in 1 second
exhaled nitric oxide
average am/pm prior nasal congestion over 15 days
asthma control test
adverse events and adverse drug reactions
repigmentation
regimen attributes composite
rtnss
trough forced expiratory volume in 1 second
bilateral endoscopic nasal polyp at week 16
elimination half life
adverse events and serious adverse events
total combined during the peak ragweed season
treatment response
combined sypmtom and medication
trough fev1
total endoscopic nasal polyps at week 52
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 5.8 hours hours
Read from the label, which states: “Elimination: Following intravenous administration, the effective plasma elimination half-life of mometasone furoate is 5.8 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
People with persistent asthma from age 5, people with allergic rhinitis or nasal polyps, and people with inflammatory skin disease — four different products with four different exposure profiles that should not be reasoned about interchangeably.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of mometasone furoate nasal spray for prophylaxis of the nasal symptoms of seasonal allergic rhinitis in pediatric patients 12 years of age and older have been established [see Adverse Reactions ( 6.1 ) and Clinical Studies ( 14.1 )].”
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-30
On older people, the label states: “A total of 280 patients above 64 years of age with allergic rhinitis or chronic rhinosinusitis with nasal polyps (age range 64 to 86 years) have been treated with mometasone furoate nasal spray for up to 3 or 4 months, respectively.”
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Mometasone is minimally absorbed systemically following nasal use, and maternal use is not expected to result in fetal exposure to the drug.”
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no available data on the presence of mometasone furoate nasal spray in human milk, the effects on the breastfed child, or the effects on milk production.”
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-30
On people with reduced liver function, the label states: “Concentrations of mometasone furoate appear to increase with severity of hepatic impairment [see Clinical Pharmacology (12.3) ] .”
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-30
Where the result stopped carrying
The serious-asthma-outcome point estimate in SPIRO was 1.22, above unity, in a design that can only show absence of a demonstrated excess
The inhaled label still carries growth effects, adrenal suppression, glaucoma and cataracts as specific warnings
Strong CYP3A4 inhibitors defeat the low-systemic-exposure design that the whole safety argument rests on
Hypothalamic-pituitary-adrenal axis testing failed to detect the growth effect that the matched beclometasone study measured directly
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Inhalation powder (Twisthaler) and pressurised HFA aerosol, aqueous nasal spray, topical cream, ointment and lotion, and a bioabsorbable sinus implant
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
The inhaled products are maintenance treatment only and are explicitly not for relief of acute bronchospasm. The nasal spray is used once daily.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold. The rest of the recorded wording: The four routes are separate products with separate evidence, and the most common error made about this drug is treating a safety finding from one route as though it applied to another.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
Not for relief of acute symptoms; rapidly deteriorating asthma requires immediate re-evaluation. Candida albicans infection of the mouth and throat may occur, with periodic monitoring advised and rinsing and spitting after each dose. Immunosuppression with potential worsening of tuberculosis and of fungal, bacterial, viral, parasitic and ocular herpes simplex infection, and a more serious or fatal course of chickenpox or measles in susceptible patients. Risk of impaired adrenal function when transferring from systemic corticosteroids, requiring slow weaning. Hypercorticism and adrenal suppression at very high dosages or at regular dosage in susceptible individuals. Strong CYP3A4 inhibitors such as ritonavir increase systemic corticosteroid effects. Paradoxical bronchospasm requires discontinuation. Growth effects in paediatric patients, and glaucoma and cataracts, are separately labelled. The most common adverse reactions at 3% or more were nasopharyngitis, headache, sinusitis, bronchitis and influenza.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Mometasone Furoate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 5424 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Inhalation powder (Twisthaler) and pressurised HFA aerosol, aqueous nasal spray, topical cream, ointment and lotion, and a bioabsorbable sinus implant
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
The nasal spray is used once daily.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold. The rest of the recorded wording: The four routes are separate products with separate evidence, and the most common error made about this drug is treating a safety finding from one route as though it applied to another.
No source is stored against this line.
What is recorded as being sold
2 products list this as an active ingredient in the United States drug directory. 2 of them contain it and nothing else.
FDA National Drug Code directory · 60429-664 · read 2026-08-29
They are sold as spray, metered, taken nasal.
FDA National Drug Code directory · 60429-664 · read 2026-08-29
The regulator's established pharmacologic class for it is corticosteroid hormone receptor agonists [moa] and corticosteroid [epc].
FDA National Drug Code directory · 60429-664 · read 2026-08-29
3 published labels name it as an active ingredient. 3 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-29
MOMETASONE FUROATE is nasal at 3 DOSAGE FORMS AND STRENGTHS Nasal spray: 50 mcg of mometasone furoate in each spray., recorded as fda label in effect 2025-07-10 in the United States.
US prescribing information · e30ca373-d9c0-4cad-b5c3-3be9c299dddc · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Mometasone Furoate studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That the 12-fold receptor affinity over dexamethasone translates into proportionally greater clinical potency — the label states the significance is unknown
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the negative intranasal growth trial clears the inhaled product, which has a different route, dose and absorbing surface
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That a normal cortisol stimulation test excludes a systemic steroid effect, when the beclometasone study found growth suppression with no HPA-axis difference
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the published SPIRO paper is the evidence the 2017 boxed-warning withdrawal rested on, when it appeared in 2019
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Mometasone Furoate are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
A one-year growth trial in children found nothing — and it was built to find it
In plain words
Ninety-eight children aged 3 to 9 with year-round hay fever were given mometasone nasal spray or placebo for a full year, with height measured on a calibrated stadiometer seven times. They grew the same. Adrenal function testing showed no suppression either.
What was measured
Change in standing height and growth rate over one year, and cosyntropin-stimulated cortisol response
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A randomised, placebo-controlled, double-blind, multicentre trial randomised 98 prepubertal children aged 3 to 9 with perennial allergic rhinitis to mometasone furoate aqueous nasal spray 100 micrograms once daily or placebo for one year, with baseline height between the 5th and 95th percentile and skeletal age within two years of chronological age. Eighty-two completed, 42 on drug and 40 on placebo, with 93% achieving at least 80% compliance. The primary safety variable was change in standing height. No growth suppression was seen; change in height at one year was 6.95 cm on mometasone against 6.35 cm on placebo, and growth rate averaged across all time points was 0.018 cm per day in both groups. Cosyntropin stimulation testing at baseline, 26 and 52 weeks showed no evidence of hypothalamic-pituitary-adrenal axis suppression at any time point. Treatment-related adverse events were 16% on drug against 22% on placebo.
Written into the record, not signed off as a reviewed claim
The same journal issue carried the opposite result for another nasal steroid
In plain words
The mometasone growth study is convincing because of what was published next to it. In the same issue of the same journal, a study of almost identical design found that intranasal beclometasone slowed growth: 5.0 cm against 5.9 cm over a year.
What was measured
Rate of change in standing height over one year in a study of matched design and size
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Skoner and colleagues randomised 100 prepubertal children aged 6 to 9 with perennial allergic rhinitis to aqueous beclometasone dipropionate 168 micrograms twice daily (n=51) or placebo (n=49) for one year, with the same entry criteria on height percentile and skeletal age and the same primary parameter, rate of change in standing height. Ninety completed. Overall growth rate was significantly slower on beclometasone in both the intention-to-treat and completer analyses; mean change in standing height at one year was 5.0 cm against 5.9 cm. The difference was evident by the one-month visit and was consistent across age and sex subgroups and across children with and without prior corticosteroid use. A z-score analysis normalising to national height data confirmed the difference was attributable to treatment rather than to a baseline imbalance. No between-group difference was found in hypothalamic-pituitary-adrenal axis assessments. A negative safety trial is only as good as the ability of that design to detect an effect, and the sibling study demonstrates the design detects 0.9 cm.
Written into the record, not signed off as a reviewed claim
The receptor-affinity ranking is quoted constantly and disclaimed by its own label
In plain words
Mometasone is routinely described as the most potent inhaled steroid, on the basis that it binds the receptor twelve times as tightly as dexamethasone and one and a half times as tightly as fluticasone. The sentence immediately after those numbers in the prescribing information says the clinical significance is unknown.
What was measured
That a 12-fold in-vitro receptor affinity over dexamethasone makes mometasone a proportionally more effective or more dangerous steroid in patients — a translation the label explicitly declines to make
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The Mechanism of Action section states the in-vitro binding affinity for the human glucocorticoid receptor as approximately 12 times dexamethasone, 7 times triamcinolone acetonide, 5 times budesonide and 1.5 times fluticasone, and immediately adds that the clinical significance of these findings is unknown. It also states that the precise mechanism of corticosteroid action in asthma is not known. Receptor affinity governs topical potency at the site of deposition; it says nothing about how much drug is deposited, how much is absorbed, or how quickly the liver removes what is. A drug can bind five times more tightly than budesonide and be dosed at a similar microgram strength, which is exactly the situation here, and that is why the ratio does not translate into a clinical ranking.
Source
ASMANEX (mometasone furoate) United States prescribing information, Clinical Pharmacology 12.1
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
SPIRO: 11,729 patients, no excess of serious asthma events, 11% fewer exacerbations
In plain words
One of the four safety trials the FDA demanded after the long-acting beta-agonist deaths. Adding formoterol to mometasone in nearly twelve thousand people produced 45 serious asthma events against 36 — all hospitalisations, none fatal — and about a tenth fewer exacerbations.
What was measured
Time to first adjudicated serious asthma outcome and to first asthma exacerbation over 26 weeks
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
SPIRO was a 26-week randomised, double-blind trial in adolescents and adults aged 12 and over with persistent asthma across 35 countries, with the primary objective of determining whether mometasone furoate-formoterol increases the risk of serious asthma outcomes — adjudicated hospitalisation, intubation or death — compared with mometasone furoate alone. Among 11,729 patients (5,868 on combination, 5,861 on mometasone alone) there were 81 serious asthma outcomes in 71 patients, every one an asthma-related hospitalisation: 45 events in 39 patients on combination against 36 events in 32 patients on mometasone alone. The hazard ratio for the first serious asthma outcome was 1.22 (95% CI 0.76 to 1.94, P=0.411). Asthma exacerbation occurred in 1,487 patients, 708 against 779, hazard ratio 0.89 (95% CI 0.80 to 0.98, P=0.021).
Written into the record, not signed off as a reviewed claim
The regulator acted on this trial more than a year before it was published
In plain words
The boxed warning came off the combination inhalers in December 2017. The combined analysis of the four trials appeared in June 2018, and this particular trial appeared in a journal in 2019. The decision and the published evidence for it did not arrive in that order.
What was measured
That the published literature is the record on which the 2017 boxed-warning withdrawal was based — the constituent trials were published in 2018 and 2019, after the decision
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
SPIRO was one of the four FDA-mandated long-acting beta-agonist safety trials. The FDA removed the boxed warning from inhaled corticosteroid and long-acting beta-agonist combination products in December 2017. The joint oversight committee’s combined analysis of all four trials in 36,010 patients was published in the New England Journal of Medicine on 28 June 2018, and SPIRO itself was published in the Journal of Allergy and Clinical Immunology in its 2019;143:1395-1402 issue. Regulators see trial data before journals do, and that is normal and correct. It is worth stating plainly because a reader tracing the evidence for the withdrawal through the published literature will find the papers dated after the decision, and may reasonably wonder which came first.
Written into the record, not signed off as a reviewed claim
A negative nasal growth trial does not clear the inhaler
In plain words
The reassuring growth result was for the nasal spray at 100 micrograms once a day. The asthma inhaler delivers more drug into a larger absorbing surface, and its label still carries warnings for growth effects in children, adrenal suppression, glaucoma and cataracts.
What was measured
Labelled systemic corticosteroid warnings for the inhaled product against the route and dose studied in the negative growth trial
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
The ASMANEX inhaled label lists, under Adverse Reactions, systemic and local corticosteroid effects including Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, growth effects in paediatric patients, and glaucoma and cataracts, each cross-referenced to its own Warnings and Precautions entry. Hypercorticism and adrenal suppression are stated to occur with very high dosages or at regular dosage in susceptible individuals, with instructions to discontinue slowly if they do. Strong CYP3A4 inhibitors such as ritonavir raise systemic corticosteroid effects. The nasal growth trial randomised 98 children to 100 micrograms once daily intranasally; extrapolating it to a twice-daily inhaled product with a different deposition site and a different absorbed fraction is a route change, not a dose comparison, and the label does not make that extrapolation.
This order is fixed in code and does not count clicks or time on the page.
What is not here
3 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A corticosteroid the label describes as binding the human glucocorticoid receptor about 12 times as tightly as dexamethasone and 1.5 times as tightly as fluticasone — while stating that the clinical significance of those ratios is unknown; its nasal spray produced no growth suppression in a one-year randomised trial in 98 children, and adding formoterol to it in 11,729 patients gave a serious-asthma-event hazard ratio of 1.22 (95% CI 0.76 to 1.94) with 11% fewer exacerbations.
Recorded evidence blocks (12)
Q1
What did Mometasone Furoate's largest trial (11744 people) and its longest (8.2 years) measure?
11744 people in Mometasone Furoate's largest registered study, 8.2 years in its longest registered window, measuring Maximum Plasma Concentration (Cmax). ClinicalTrials.gov · 2026-09-01
63 phase3, 44 phase4, 28 phase2, 12 na, 11 phase1, 4 na or unstated, 2 early phase1; NCT00927329; 2017-04; no ageing endpoint recorded. Last human test completed 2026, NCT06691113.
Interpretation These counts include studies where Mometasone Furoate was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase3
63
phase4
44
phase2
28
na
12
phase1
11
na or unstated
4
2 more recorded rows
early phase1
2
Last recorded human testNCT06691113
2026-08-12
recorded 2026-09-01 · last checked 2026-09-04
Q2
Mometasone Furoate was tested only in human — what did it show?
"Study stopped early due to slow accrual."; 19 of 162 registered studies
Show the evidence
Trial
NCT00361439
terminated; "Study stopped early due to slow accrual."
NCT00442351
terminated; "Slow Enrollment"
NCT00461812
terminated; "by sponsor due to failure to recruit patients who had mild persistent asthma who were not already on Advair 250/50 or 500/50."
NCT00491374
terminated; "Very poor enrollment"
NCT00553891
withdrawn; "No enrollment because of war in the study country."
NCT00927329
withdrawn; "Original PI left institution."
13 further recorded trials
NCT00967967
suspended; "Awaiting results from sub analysis to decide if study continuesé"
NCT01616160
terminated; "Inability to recruit additional subjects."
NCT01671852
withdrawn; "Could not obtain funding."
NCT01861145
withdrawn; "Unable to sufficiently enroll or collect follow-up"
NCT02113267
terminated; "Combination slow recruitment, short shelf life for placebo and insufficient funding for further drug production (probably anyway sufficient number included)."
NCT02953366
withdrawn; "Sponsor decision"
NCT02953379
withdrawn; "Sponsor decision"
NCT03323866
terminated; "Difficulty with recruitment"
NCT03605537
withdrawn; "Study terminated due to lack of funding."
NCT04499235
terminated; "The study was prematurely terminated by the Sponsor due to operational challenges stemming from the coronavirus disease 2019 (COVID-19) pandemic, treatment limitations, rarity of the disease, and drug supply considerations."
NCT04670653
withdrawn; "Sponsor decision"
NCT05120986
withdrawn; "Novartis Farma - Produtos Farmaceuticos S.A. no longer commercializes the product."
NCT05887843
terminated; "Business decision (no safety concerns)."
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Mometasone Furoate used mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID — over how long?
Human studies of Mometasone Furoate used "mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID". ClinicalTrials.gov · 2026-09-01
20 recorded entries; human; also "Mometasone furoate MDI (MF MDI) 200 mcg", "Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID", "Mometasone furoate 50 mcg Rescue Treatment"
Show the evidence
human
NCT00383240
mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID
NCT00383240
Mometasone furoate MDI (MF MDI) 200 mcg
NCT00383552
Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID
NCT00550550
Mometasone furoate 50 mcg Rescue Treatment
NCT00562159
Mometasone 50 mcg Rescue Treatment
NCT00635882
mometasone furoate/formoterol 100/10 mcg
14 more recorded rows
humanNCT00635882
mometasone furoate/formoterol 200/10 mcg
humanNCT00635882
mometasone furoate/formoterol 400/10 mcg
humanNCT01210170
mometasone 400 mcg
humanNCT01210170
mometasone 200 mcg
humanNCT01471340
Mometasone Furoate/Formoterol MDI 100/5 mcg
humanNCT01471340
Mometasone Furoate/Formoterol MDI 200/5 mcg
humanNCT01471340
Mometasone Furoate MDI 100 mcg
humanNCT01471340
Mometasone Furoate MDI 200 mcg
humanNCT01502371
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg
humanNCT01502371
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg
humanNCT01502371
Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg
humanNCT01502371
Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg
humanNCT02066298
Mometasone 220mcg BID
humanNCT02125253
Mometasone Furoate Nasal Spray, 50 mcg
recorded 2026-09-01 · last checked 2026-09-04
Q5
Mometasone Furoate's half-life is 5.8 hours — which schedules were studied?
5.8 hours, the half-life Mometasone Furoate's label states. openfda-label · 0c6d63da-41bc-4894-bead-198e66c848ac · 2026-08-30
bioavailability 1% %.
Show the evidence
half life
5.8 hours hours; Elimination: Following intravenous administration, the effective plasma elimination half-life of mometasone furoate is 5.8 hours.
tmax
Absorption Adult Healthy Subjects: Following oral inhalation of single doses of ASMANEX HFA, mometasone furoate was absorbed in healthy subjects with median T max values ranging from 0.50 to 2 hours.
bioavailability
1% %; 12.3 Pharmacokinetics Absorption : Mometasone furoate monohydrate administered as a nasal spray suspension has very low bioavailability (<1%) in plasma using a sensitive assay with a lower quantitation limit (LOQ) of 0.25 pcg/mL.
metabolism
Metabolism Studies have shown that mometasone furoate is primarily and extensively metabolized in the liver of all species investigated and undergoes extensive metabolism to multiple metabolites.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Could one person measure Mometasone Furoate's effect on apnea hypopnea index?
Apnea hypopnea index: measured in Mometasone Furoate's trials.
Interpretation apnea hypopnea index is the recorded endpoint.
Show the evidence
biomarkers
apnea hypopnea index; 2026-09-01
total combined symptom over the entire grass pollen season; 2026-09-01
global assessment; 2026-09-01
pharmacokinetic parameters; 2026-09-01
forced expiratory volume in 1 second; 2026-09-01
exhaled nitric oxide; 2026-09-01
14 more recorded rows
biomarkers
average am/pm prior nasal congestion over 15 days; 2026-09-01
biomarkers
4 nasal symptom from baseline at week 2; 2026-09-01
biomarkers
4 nasal symptom after 2 weeks; 2026-09-01
biomarkers
total nasal symptom; 2026-09-01
biomarkers
asthma control test; 2026-09-01
biomarkers
adverse events and adverse drug reactions; 2026-09-01
biomarkers
repigmentation; 2026-09-01
biomarkers
regimen attributes composite; 2026-09-01
biomarkers
rtnss; 2026-09-01
biomarkers
reflective total nasal symptom; 2026-09-01
biomarkers
trough forced expiratory volume in 1 second; 2026-09-01
biomarkers
bilateral endoscopic nasal polyp at week 16; 2026-09-01
0; NCT00491374; PHASE4; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; TERMINATED
Q7
Which of 4 nasal symptom after 2 weeks, 4 nasal symptom from baseline at week 2 and adverse events did Mometasone Furoate's trials measure?
4 nasal symptom after 2 weeks, 4 nasal symptom from baseline at week 2 and adverse events lead 40 outcome terms across Mometasone Furoate's trials. ClinicalTrials.gov · 2026-09-01
pharmacokinetic parameters, forced expiratory volume in 1 second, exhaled nitric oxide, average am/pm prior nasal congestion over 15 days, 4 nasal symptom from baseline at week 2 and 4 nasal symptom after 2 weeks follow.
Show the evidence
apnea hypopnea index
1
total combined symptom over the entire grass pollen season
1
global assessment
1
pharmacokinetic parameters
1
forced expiratory volume in 1 second
1
exhaled nitric oxide
1
14 more recorded rows
average am/pm prior nasal congestion over 15 days
1
4 nasal symptom from baseline at week 2
1
4 nasal symptom after 2 weeks
1
total nasal symptom
1
asthma control test
1
adverse events and adverse drug reactions
1
repigmentation
1
regimen attributes composite
1
rtnss
1
reflective total nasal symptom
1
trough forced expiratory volume in 1 second
1
bilateral endoscopic nasal polyp at week 16
1
maximum plasma concentration
1
time to reach maximum concentration
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Mometasone Furoate's 9 ongoing trials reports first?
Evaluation of hair regrowth in alopecia areata using SALT score.; Rate of improvement in TNSS scores; latest 2031-01-29
Show the evidence
Trial
NCT06399783
"Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata"; n 54; "Evaluation of hair regrowth in alopecia areata using SALT score."; 2027-12-01
NCT06436534
"Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis"; n 50; "Rate of improvement in TNSS scores"; 2026-12
NCT06801353
"A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps"; n 90; "Nasal Polyps Score (NPS)"; 2026-07-01
NCT06834347
"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps"; n 231; "Change from baseline in the endoscopic NPS"; 2027-09-16
NCT06834360
"A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps"; n 216; "Change from baseline in the endoscopic NPS"; 2027-10-11
NCT06914908
"Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study"; n 71; "Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)"; 2031-01-29
3 further recorded trials
NCT07525505
"Nigella Sativa Oil for Eczematous Otitis Externa"; n 85; "Change in objective inflammatory findings of the external ear from baseline to Day 10"; 2026-07
NCT07532993
"Comparison of Antihistamine and Antileukotriene Add-On Therapy to Intranasal Corticosteroid in Allergic Rhinitis"; n 32; "Change in Total Nasal Symptom Score (TNSS)"; 2027-05
NCT07784491
"Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis"; n 150; "Change From Baseline in Total Nasal Symptom Score"; 2027-01-20
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 47 trials of Mometasone Furoate posted no result?
Posted no result
47 of 47 completed trials
Registrations
NCT00817817, NCT00835094, NCT00975741, NCT00750750, NCT00783237 and NCT00834119, and 41 more
Completion dates
oldest 2003-05-01; newest 2024-04-23
Show the evidence
Trial
NCT00817817
2003-05-01
NCT00835094
2003-07-01
NCT00975741
2003-08
NCT00750750
2003-09-01
NCT00783237
2004-02-21
NCT00834119
2004-04-01
14 further recorded trials
NCT00751075
2004-06-22
NCT00779545
2004-08-06
NCT00763529
2005-01-01
NCT00783458
2005-01-01
NCT00817050
2005-01-01
NCT00779740
2005-04-01
NCT00731185
2005-09-01
NCT00732368
2006-01-01
NCT00711165
2006-08
NCT00224523
2007-02
NCT00544687
2007-11
NCT00557739
2008-01
NCT00662883
2008-02
NCT00721331
2008-09
Q10
At the median, Mometasone Furoate's trials enrolled 103.5 people — anything larger?
Median enrolment
103.5
Largest enrolment
11744
Registered trials counted
162
Q11
What do 5424 spontaneous reports say about Mometasone Furoate — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Mometasone Furoate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 5424 reaction mentions were counted: poor quality device used 1604; dyspnoea 1171; cough 618; asthma 486. open-targets-adr · CHEMBL1161 · 2026-06-24
Show the evidence
poor quality device used
1604
dyspnoea
1171
cough
618
asthma
486
wheezing
335
product dose omission issue
322
4 more recorded rows
gastrooesophageal reflux disease
293
chest discomfort
219
somnolence
193
coma
183
recorded 2026-06-24 · last checked 2026-09-04
Q12
Mometasone Furoate and CYP3A4: shared by which compounds?
CYP3A4 appear in Mometasone Furoate's recorded interaction sentences, 1 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP3A4pharmacokinetics
In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4 (CYP3A4).
recorded 2026-08-30 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 9 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.